After much ado, Seagen Inc. is finally being acquired — by Pfizer Inc. The $43 billion proposed deal should quell investor calls for Pfizer to do something splashier with its Covid cash, and could put Pfizer into a leadership position in oncology. But Pfizer still has a lot of work to do to convince investors that its huge bet on Seagen is sound.
One word came up over and over again as Pfizer laid out its case to investors Monday morning: durability. Pfizer argued that Seagen can provide a steady and long-lasting revenue stream that will help fill the $17 billion hole it is facing as key products lose patent protection between 2025 and 2030.
Pfizer makes a decent argument. Its